Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2012

01.05.2012 | Review

Risk prediction models of breast cancer: a systematic review of model performances

verfasst von: Thunyarat Anothaisintawee, Yot Teerawattananon, Chollathip Wiratkapun, Vijj Kasamesup, Ammarin Thakkinstian

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

The number of risk prediction models has been increasingly developed, for estimating about breast cancer in individual women. However, those model performances are questionable. We therefore have conducted a study with the aim to systematically review previous risk prediction models. The results from this review help to identify the most reliable model and indicate the strengths and weaknesses of each model for guiding future model development. We searched MEDLINE (PubMed) from 1949 and EMBASE (Ovid) from 1974 until October 2010. Observational studies which constructed models using regression methods were selected. Information about model development and performance were extracted. Twenty-five out of 453 studies were eligible. Of these, 18 developed prediction models and 7 validated existing prediction models. Up to 13 variables were included in the models and sample sizes for each study ranged from 550 to 2,404,636. Internal validation was performed in four models, while five models had external validation. Gail and Rosner and Colditz models were the significant models which were subsequently modified by other scholars. Calibration performance of most models was fair to good (expected/observe ratio: 0.87–1.12), but discriminatory accuracy was poor to fair both in internal validation (concordance statistics: 0.53–0.66) and in external validation (concordance statistics: 0.56–0.63). Most models yielded relatively poor discrimination in both internal and external validation. This poor discriminatory accuracy of existing models might be because of a lack of knowledge about risk factors, heterogeneous subtypes of breast cancer, and different distributions of risk factors across populations. In addition the concordance statistic itself is insensitive to measure the improvement of discrimination. Therefore, the new method such as net reclassification index should be considered to evaluate the improvement of the performance of a new develop model.
Literatur
1.
Zurück zum Zitat Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics 2002. CA Cancer J Clinicians 55(2):74–108CrossRef Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics 2002. CA Cancer J Clinicians 55(2):74–108CrossRef
2.
Zurück zum Zitat Ferlay J, Bray F, Parkin DM, Pisani P eds (2001) Globalcan 2000. IARC Press, Lyon Ferlay J, Bray F, Parkin DM, Pisani P eds (2001) Globalcan 2000. IARC Press, Lyon
3.
Zurück zum Zitat VH BF (2002) IARC handbooks of cancer prevention. IARC Press, Lyon VH BF (2002) IARC handbooks of cancer prevention. IARC Press, Lyon
5.
Zurück zum Zitat Steyerberg EW (ed) (2009) Clinical prediction models a practical approach to development, validation, and updating. Springer Science + Business Media LLC, New York Steyerberg EW (ed) (2009) Clinical prediction models a practical approach to development, validation, and updating. Springer Science + Business Media LLC, New York
6.
Zurück zum Zitat Boyle P, Mezzetti M, La Vecchia C, Franceschi S, Decarli A, Robertson C (2004) Contribution of three components to individual cancer risk predicting breast cancer risk in Italy. Eur J Cancer Prev 13(3):183–191PubMedCrossRef Boyle P, Mezzetti M, La Vecchia C, Franceschi S, Decarli A, Robertson C (2004) Contribution of three components to individual cancer risk predicting breast cancer risk in Italy. Eur J Cancer Prev 13(3):183–191PubMedCrossRef
7.
Zurück zum Zitat Chlebowski RT, Anderson GL, Lane DS, Aragaki AK, Rohan T, Yasmeen S, Sarto G, Rosenberg CA, Hubbell FA (2007) Predicting risk of breast cancer in postmenopausal women by hormone receptor status. J Natl Cancer Inst 99(22):1695–1705PubMedCrossRef Chlebowski RT, Anderson GL, Lane DS, Aragaki AK, Rohan T, Yasmeen S, Sarto G, Rosenberg CA, Hubbell FA (2007) Predicting risk of breast cancer in postmenopausal women by hormone receptor status. J Natl Cancer Inst 99(22):1695–1705PubMedCrossRef
8.
Zurück zum Zitat Colditz GA, Rosner B (2000) Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses’ Health Study. Am J Epidemiol 152(10):950–964PubMedCrossRef Colditz GA, Rosner B (2000) Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses’ Health Study. Am J Epidemiol 152(10):950–964PubMedCrossRef
9.
Zurück zum Zitat Colditz GA, Rosner BA, Chen WY, Holmes MD, Hankinson SE (2004) Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst 96(3):218–228PubMedCrossRef Colditz GA, Rosner BA, Chen WY, Holmes MD, Hankinson SE (2004) Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst 96(3):218–228PubMedCrossRef
10.
Zurück zum Zitat Decarli A, Calza S, Masala G, Specchia C, Palli D, Gail MH (2006) Gail model for prediction of absolute risk of invasive breast cancer: independent evaluation in the Florence-European prospective investigation into cancer and nutrition cohort. J Natl Cancer Inst 98(23):1686–1693PubMedCrossRef Decarli A, Calza S, Masala G, Specchia C, Palli D, Gail MH (2006) Gail model for prediction of absolute risk of invasive breast cancer: independent evaluation in the Florence-European prospective investigation into cancer and nutrition cohort. J Natl Cancer Inst 98(23):1686–1693PubMedCrossRef
11.
Zurück zum Zitat Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, Mulvihill JJ (1989) Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81(24):1879–1886PubMedCrossRef Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, Mulvihill JJ (1989) Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81(24):1879–1886PubMedCrossRef
12.
Zurück zum Zitat Lee EO, Ahn SH, You C, Lee DS, Han W, Choe KJ, Noh DY (2004) Determining the main risk factors and high-risk groups of breast cancer using a predictive model for breast cancer risk assessment in South Korea. Cancer Nurs 27(5):400–406PubMedCrossRef Lee EO, Ahn SH, You C, Lee DS, Han W, Choe KJ, Noh DY (2004) Determining the main risk factors and high-risk groups of breast cancer using a predictive model for breast cancer risk assessment in South Korea. Cancer Nurs 27(5):400–406PubMedCrossRef
13.
Zurück zum Zitat Rosner B, Colditz GA (1996) Nurses’ health study: log-incidence mathematical model of breast cancer incidence. J Natl Cancer Inst 88(6):359–364PubMedCrossRef Rosner B, Colditz GA (1996) Nurses’ health study: log-incidence mathematical model of breast cancer incidence. J Natl Cancer Inst 88(6):359–364PubMedCrossRef
14.
Zurück zum Zitat Barlow WE, White E, Ballard-Barbash R, Vacek PM, Titus-Ernstoff L, Carney PA, Tice JA, Buist DS, Geller BM, Rosenberg R, Yankaskas BC, Kerlikowske K (2006) Prospective breast cancer risk prediction model for women undergoing screening mammography. J Natl Cancer Inst 98(17):1204–1214. doi:10.1093/jnci/djj331 PubMedCrossRef Barlow WE, White E, Ballard-Barbash R, Vacek PM, Titus-Ernstoff L, Carney PA, Tice JA, Buist DS, Geller BM, Rosenberg R, Yankaskas BC, Kerlikowske K (2006) Prospective breast cancer risk prediction model for women undergoing screening mammography. J Natl Cancer Inst 98(17):1204–1214. doi:10.​1093/​jnci/​djj331 PubMedCrossRef
15.
Zurück zum Zitat Chen J, Pee D, Ayyagari R, Graubard B, Schairer C, Byrne C, Benichou J, Gail MH (2006) Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density. J Natl Cancer Inst 98(17):1215–1226PubMedCrossRef Chen J, Pee D, Ayyagari R, Graubard B, Schairer C, Byrne C, Benichou J, Gail MH (2006) Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density. J Natl Cancer Inst 98(17):1215–1226PubMedCrossRef
16.
Zurück zum Zitat Gail MH, Costantino JP, Pee D, Bondy M, Newman L, Selvan M, Anderson GL, Malone KE, Marchbanks PA, McCaskill-Stevens W, Norman SA, Simon MS, Spirtas R, Ursin G, Bernstein L (2007) Projecting individualized absolute invasive breast cancer risk in African American women. J Natl Cancer Inst 99(23):1782–1792PubMedCrossRef Gail MH, Costantino JP, Pee D, Bondy M, Newman L, Selvan M, Anderson GL, Malone KE, Marchbanks PA, McCaskill-Stevens W, Norman SA, Simon MS, Spirtas R, Ursin G, Bernstein L (2007) Projecting individualized absolute invasive breast cancer risk in African American women. J Natl Cancer Inst 99(23):1782–1792PubMedCrossRef
17.
Zurück zum Zitat Novotny J, Pecen L, Petruzelka L, Svobodnik A, Dusek L, Danes J, Skovajsova M (2006) Breast cancer risk assessment in the Czech female population—an adjustment of the original Gail model. Breast Cancer Res Treat 95(1):29–35PubMedCrossRef Novotny J, Pecen L, Petruzelka L, Svobodnik A, Dusek L, Danes J, Skovajsova M (2006) Breast cancer risk assessment in the Czech female population—an adjustment of the original Gail model. Breast Cancer Res Treat 95(1):29–35PubMedCrossRef
18.
Zurück zum Zitat Rosner B, Colditz GA, Iglehart JD, Hankinson SE (2008) Risk prediction models with incomplete data with application to prediction of estrogen receptor-positive breast cancer: prospective data from the Nurses’ Health Study. Breast Cancer Res BCR 10(4):R55CrossRef Rosner B, Colditz GA, Iglehart JD, Hankinson SE (2008) Risk prediction models with incomplete data with application to prediction of estrogen receptor-positive breast cancer: prospective data from the Nurses’ Health Study. Breast Cancer Res BCR 10(4):R55CrossRef
19.
Zurück zum Zitat Tamimi RM, Rosner B, Colditz GA Evaluation of a breast cancer risk prediction model expanded to include category of prior benign breast disease lesion. Cancer. doi: 10.1002/cncr.25386 Tamimi RM, Rosner B, Colditz GA Evaluation of a breast cancer risk prediction model expanded to include category of prior benign breast disease lesion. Cancer. doi: 10.​1002/​cncr.​25386
20.
Zurück zum Zitat Tice JA, Cummings SR, Smith-Bindman R, Ichikawa L, Barlow WE, Kerlikowske K (2008) Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model. Ann Intern Med 148(5):337–347PubMed Tice JA, Cummings SR, Smith-Bindman R, Ichikawa L, Barlow WE, Kerlikowske K (2008) Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model. Ann Intern Med 148(5):337–347PubMed
21.
Zurück zum Zitat Tice JA, Cummings SR, Ziv E, Kerlikowske K (2005) Mammographic breast density and the Gail model for breast cancer risk prediction in a screening population. Breast Cancer Res Treat 94(2):115–122PubMedCrossRef Tice JA, Cummings SR, Ziv E, Kerlikowske K (2005) Mammographic breast density and the Gail model for breast cancer risk prediction in a screening population. Breast Cancer Res Treat 94(2):115–122PubMedCrossRef
22.
Zurück zum Zitat Tice JA, Miike R, Adduci K, Petrakis NL, King E, Wrensch MR (2005) Nipple aspirate fluid cytology and the Gail model for breast cancer risk assessment in a screening population. Cancer Epidemiol Biomarkers Prev 14(2):324–328PubMedCrossRef Tice JA, Miike R, Adduci K, Petrakis NL, King E, Wrensch MR (2005) Nipple aspirate fluid cytology and the Gail model for breast cancer risk assessment in a screening population. Cancer Epidemiol Biomarkers Prev 14(2):324–328PubMedCrossRef
23.
Zurück zum Zitat Ueda K, Tsukuma H, Tanaka H, Ajiki W, Oshima A (2003) Estimation of individualized probabilities of developing breast cancer for Japanese women. Breast cancer (Tokyo, Japan) 10(1):54–62CrossRef Ueda K, Tsukuma H, Tanaka H, Ajiki W, Oshima A (2003) Estimation of individualized probabilities of developing breast cancer for Japanese women. Breast cancer (Tokyo, Japan) 10(1):54–62CrossRef
24.
Zurück zum Zitat Bondy ML, Lustbader ED, Halabi S, Ross E, Vogel VG (1994) Validation of a breast cancer risk assessment model in women with a positive family history. J Natl Cancer Inst 86(8):620–625PubMedCrossRef Bondy ML, Lustbader ED, Halabi S, Ross E, Vogel VG (1994) Validation of a breast cancer risk assessment model in women with a positive family history. J Natl Cancer Inst 86(8):620–625PubMedCrossRef
25.
Zurück zum Zitat Costantino JP, Gail MH, Pee D, Anderson S, Redmond CK, Benichou J, Wieand HS (1999) Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 91(18):1541–1548PubMedCrossRef Costantino JP, Gail MH, Pee D, Anderson S, Redmond CK, Benichou J, Wieand HS (1999) Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 91(18):1541–1548PubMedCrossRef
26.
Zurück zum Zitat McKian KP, Reynolds CA, Visscher DW, Nassar A, Radisky DC, Vierkant RA, Degnim AC, Boughey JC, Ghosh K, Anderson SS, Minot D, Caudill JL, Vachon CM, Frost MH, Pankratz VS, Hartmann LC (2009) Novel breast tissue feature strongly associated with risk of breast cancer. J Clin Oncol 27(35):5893–5898PubMedCrossRef McKian KP, Reynolds CA, Visscher DW, Nassar A, Radisky DC, Vierkant RA, Degnim AC, Boughey JC, Ghosh K, Anderson SS, Minot D, Caudill JL, Vachon CM, Frost MH, Pankratz VS, Hartmann LC (2009) Novel breast tissue feature strongly associated with risk of breast cancer. J Clin Oncol 27(35):5893–5898PubMedCrossRef
27.
Zurück zum Zitat Rockhill B, Byrne C, Rosner B, Louie MM, Colditz G (2003) Breast cancer risk prediction with a log-incidence model: evaluation of accuracy. J Clin Epidemiol 56(9):856–861PubMedCrossRef Rockhill B, Byrne C, Rosner B, Louie MM, Colditz G (2003) Breast cancer risk prediction with a log-incidence model: evaluation of accuracy. J Clin Epidemiol 56(9):856–861PubMedCrossRef
28.
Zurück zum Zitat Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA (2001) Validation of the Gail et al. Model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst 93(5):358–366PubMedCrossRef Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA (2001) Validation of the Gail et al. Model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst 93(5):358–366PubMedCrossRef
29.
Zurück zum Zitat Schonfeld SJ, Pee D, Greenlee RT, Hartge P, Lacey JV, Jr., Park Y, Schatzkin A, Visvanathan K, Pfeiffer RM (2010) Effect of changing breast cancer incidence rates on the calibration of the Gail model. J Clin Oncol 28(14):2411–2417. doi: 10.1200/JCO.2009.25.2767 Schonfeld SJ, Pee D, Greenlee RT, Hartge P, Lacey JV, Jr., Park Y, Schatzkin A, Visvanathan K, Pfeiffer RM (2010) Effect of changing breast cancer incidence rates on the calibration of the Gail model. J Clin Oncol 28(14):2411–2417. doi: 10.​1200/​JCO.​2009.​25.​2767
30.
Zurück zum Zitat Ulusoy C, Kepenekci I, Kose K, Aydintug S, Cam R (2010) Applicability of the Gail model for breast cancer risk assessment in Turkish female population and evaluation of breastfeeding as a risk factor. Breast Cancer Res Treat 120(2):419–424PubMedCrossRef Ulusoy C, Kepenekci I, Kose K, Aydintug S, Cam R (2010) Applicability of the Gail model for breast cancer risk assessment in Turkish female population and evaluation of breastfeeding as a risk factor. Breast Cancer Res Treat 120(2):419–424PubMedCrossRef
31.
33.
Zurück zum Zitat Pencina MJ, D’Agostino RB Sr, D’Agostino RB Jr, Vasan RS (2008) Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27(2):157–172 discussion 207–112PubMedCrossRef Pencina MJ, D’Agostino RB Sr, D’Agostino RB Jr, Vasan RS (2008) Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27(2):157–172 discussion 207–112PubMedCrossRef
34.
Zurück zum Zitat Altman DG, Royston P (2000) What do we mean by validating a prognostic model? Stat Med 19(4):453–473PubMedCrossRef Altman DG, Royston P (2000) What do we mean by validating a prognostic model? Stat Med 19(4):453–473PubMedCrossRef
35.
Zurück zum Zitat Peduzzi P, Concato J, Feinstein AR, Holford TR (1995) Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol 48(12):1503–1510PubMedCrossRef Peduzzi P, Concato J, Feinstein AR, Holford TR (1995) Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol 48(12):1503–1510PubMedCrossRef
37.
Zurück zum Zitat Pepe MS, Janes H, Longton G, Leisenring W, Newcomb P (2004) Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol 159(9):882–890PubMedCrossRef Pepe MS, Janes H, Longton G, Leisenring W, Newcomb P (2004) Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol 159(9):882–890PubMedCrossRef
38.
Zurück zum Zitat Haynes RB, Sackett DL, Guyatt GH (eds) (2006) Clinical epidemiology: how to do clinical practice research, 3rd edn. Lippincott Williams and Wilkins, Philadelphia Haynes RB, Sackett DL, Guyatt GH (eds) (2006) Clinical epidemiology: how to do clinical practice research, 3rd edn. Lippincott Williams and Wilkins, Philadelphia
39.
Zurück zum Zitat Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer (1997). Lancet 350(9084):1047–1059 Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer (1997). Lancet 350(9084):1047–1059
40.
Zurück zum Zitat Ewertz M, Duffy SW, Adami HO, Kvale G, Lund E, Meirik O, Mellemgaard A, Soini I, Tulinius H (1990) Age at first birth, parity and risk of breast cancer: a meta-analysis of 8 studies from the Nordic countries. Int J Cancer 46(4):597–603PubMedCrossRef Ewertz M, Duffy SW, Adami HO, Kvale G, Lund E, Meirik O, Mellemgaard A, Soini I, Tulinius H (1990) Age at first birth, parity and risk of breast cancer: a meta-analysis of 8 studies from the Nordic countries. Int J Cancer 46(4):597–603PubMedCrossRef
41.
Zurück zum Zitat Pharoah PD, Day NE, Duffy S, Easton DF, Ponder BA (1997) Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer 71(5):800–809PubMedCrossRef Pharoah PD, Day NE, Duffy S, Easton DF, Ponder BA (1997) Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer 71(5):800–809PubMedCrossRef
42.
Zurück zum Zitat North RA, McCowan LME, Dekker GA, Poston L, Chan EHY, Stewart AW, Black MA, Taylor RS, Walker JJ, Baker PN, Kenny LC (2011) Clinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort. BMJ (Clinical research ed) 342:d1875s. doi: 10.1136/bmj.d1875 North RA, McCowan LME, Dekker GA, Poston L, Chan EHY, Stewart AW, Black MA, Taylor RS, Walker JJ, Baker PN, Kenny LC (2011) Clinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort. BMJ (Clinical research ed) 342:d1875s. doi: 10.​1136/​bmj.​d1875
43.
Zurück zum Zitat Tyrer J, Duffy SW, Cuzick J (2004) A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 23(7):1111–1130PubMedCrossRef Tyrer J, Duffy SW, Cuzick J (2004) A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 23(7):1111–1130PubMedCrossRef
44.
Zurück zum Zitat Amir E, Evans DG, Shenton A, Lalloo F, Moran A, Boggis C, Wilson M, Howell A (2003) Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J Med Genet 40(11):807–814PubMedCrossRef Amir E, Evans DG, Shenton A, Lalloo F, Moran A, Boggis C, Wilson M, Howell A (2003) Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J Med Genet 40(11):807–814PubMedCrossRef
46.
Zurück zum Zitat Cook NR, Buring JE, Ridker PM (2006) The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med 145(1):21–29PubMed Cook NR, Buring JE, Ridker PM (2006) The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med 145(1):21–29PubMed
47.
Zurück zum Zitat Janes H, Pepe MS, Gu W (2008) Assessing the value of risk predictions by using risk stratification tables. Ann Intern Med 149(10):751–760PubMed Janes H, Pepe MS, Gu W (2008) Assessing the value of risk predictions by using risk stratification tables. Ann Intern Med 149(10):751–760PubMed
48.
Metadaten
Titel
Risk prediction models of breast cancer: a systematic review of model performances
verfasst von
Thunyarat Anothaisintawee
Yot Teerawattananon
Chollathip Wiratkapun
Vijj Kasamesup
Ammarin Thakkinstian
Publikationsdatum
01.05.2012
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2012
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-011-1853-z

Weitere Artikel der Ausgabe 1/2012

Breast Cancer Research and Treatment 1/2012 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.